Novel Acne Vaccine Targeting Inflammation-Inducing Agent of P. acnes

Tech ID: liu000876



Acne is the most common skin condition in the United States.  Traditional acne treatments work by reducing oil production, speeding up skin cell turnover, fighting bacterial infection, reducing the inflammation, or doing all four. These types of acne treatments include over-the-counter topical treatments, antibiotics, oral contraceptives and cosmetic procedures. However, these traditional treatments all have shortcomings and risks. There is clearly a need for a vaccine for treating, preventing, reducing the likelihood of, and reducing the severity of acne.


Technology Description 

P. acnes bacteria are linked to the skin condition of acne. Researchers at the Cedars-Sinai Medical Center (CSMC) have discovered a new target of P. acnes and are working on developing a vaccine for acne.



Our vaccine utilizes a novel target that:


1. appears to induce pro-inflammatory pathways strongly associated with acne pathogenesis including TLR2, NFκβ activation, and IL-1β,


2. is unique among human commensals and pathogens and therefore could explain why P. acnes is hyper-inflammatory among all skin commensals and pathogens.



• Inventors are working on the biology and the mechanism and establishing animal model for testing the vaccine. Proof-of-concept study of the vaccination is being pursued.

• We are looking for partners to further develop the technology and enable clinical testing.


Intellectual Property

PCT application PCT/US2016/044793 nationalized in US and EU.


Patent Information:
For Information, Contact:
Wenyue Du
Senior Associate - IP Management & Licensing
George Liu
Stacey Kolar
Inflammatory Disorders